Skip to main content

Medtronic Pledges Support to End Obesity Stigma

DUBLIN, March 03, 2020 (GLOBE NEWSWIRE) — Coinciding with World Obesity Day, Medtronic further demonstrated its ongoing commitment to increasing patient access to quality care by taking the Pledge to Eradicate Weight Stigma. This action aligns with a joint consensus statement on the causes and negative consequences of obesity bias published today in Nature Medicine by a team of experts led by Professor Francesco Rubino from King’s College London.According to the World Health Organization, more than 650 million people worldwide are living with obesity, which is amplified by numerous factors, many of which are beyond an individual’s control. In supporting the pledge, Medtronic condemns the use of stigmatizing language, images, attitudes, policies, and weight-based discrimination, wherever they occur, and commits to: Treat individuals with overweight and obesity with dignity and respect;  Refrain from using stereotyping language, images and narratives; Encourage educational initiatives aimed at eradicating weight bias through dissemination of modern-day knowledge of obesity and body weight regulation; and Support initiatives aimed at preventing weight-based discrimination in the workplace, education, and healthcare settings.The pledge and international consensus statement renouncing obesity bias supports a growing body of scientific evidence on biological, genetic and environmental contributors to obesity. Findings from the independent Obesity Attitudes, Stigma and Knowledge study (ASK) published today in Lancet Diabetes & Endocrinology demonstrates that for people living with obesity, bias against them is pervasive. By participating in the pledge, Medtronic aims to foster greater understanding of obesity and related diseases across the care continuum, and help patients gain access to critical care by reducing weight-related stigma.World Obesity Day
As a primary sponsor of World Obesity Day, Medtronic is supporting the world’s leading obesity organizations by leading activities and events – including hospital open days, patient education engagements, HCP roadshows, media and social media campaigns, and roundtable events with policymakers – in more than 20 countries. These events will continue to raise awareness of the causes and impacts of obesity, and the need for greater access to evidence-based treatments across the globe.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.-end-
John Jordan
Public Relations
+1-508-452-4891
Ryan Weispfenning
Investor Relations
+1-763-505-4626

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.